Evogene Completes Sale of Lavie Bio's Activities to ICL, Transferring Key Technology Platforms

Reuters

08 Jul

Evogene Completes Sale of Lavie Bio's Activities to ICL, Transferring Key Technology Platforms

Evogene Ltd. has announced the completion of its transaction with ICL Group Ltd., involving the divestiture of the majority of Lavie Bio Ltd.'s activities and assets. This transaction includes the transfer of Lavie Bio's proprietary Biology Driven Design technology platform, microbial bank, and pipeline of advanced development programs to ICL. Evogene has also transferred its MicroBoost AI for AG platform to ICL. The strategic move aligns with Evogene's strategy to enhance the value of its subsidiaries and technology, while ICL aims to strengthen its position in the ag-biologicals market by integrating Lavie Bio's capabilities with its own expertise and global reach. Existing strategic partnerships and commercial agreements of Lavie Bio remain unaffected and under its ownership.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Evogene Ltd. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001178913-25-002325), on July 08, 2025, and is solely responsible for the information contained therein.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

1
2
3
4
5
6
7
8
9
10

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www-web.itiger.com/news/2549493205"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2549493205\",edition:\"fundamental\",,,undefined,":{"share":"https://ttm.financial/m/news/2549493205?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-07-08 19:00","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2549493205","market":"fut","top_or_hot":-1,"title":"Evogene Completes Sale of Lavie Bio's Activities to ICL, Transferring Key Technology Platforms","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      Evogene Completes Sale of Lavie Bio's Activities to ICL, Transferring Key Technology Platforms\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        <a href=\"https://laohu8.com/S/EVGN\">Evogene Ltd.</a> has announced the completion of its transaction with ICL Group Ltd., involving the divestiture of the majority of Lavie Bio Ltd.'s activities and assets. This transaction includes the transfer of Lavie Bio's proprietary Biology Driven Design technology platform, microbial bank, and pipeline of advanced development programs to ICL. Evogene has also transferred its MicroBoost AI for AG platform to ICL. The strategic move aligns with Evogene's strategy to enhance the value of its subsidiaries and technology, while ICL aims to strengthen its position in the ag-biologicals market by integrating Lavie Bio's capabilities with its own expertise and global reach. Existing strategic partnerships and commercial agreements of Lavie Bio remain unaffected and under its ownership.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Evogene Ltd. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001178913-25-002325), on July 08, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Evogene Completes Sale of Lavie Bio's Activities to ICL, Transferring Key Technology Platforms</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nEvogene Completes Sale of Lavie Bio's Activities to ICL, Transferring Key Technology Platforms\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2025-07-08 19:00</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      Evogene Completes Sale of Lavie Bio's Activities to ICL, Transferring Key Technology Platforms\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        <a href=\"https://laohu8.com/S/EVGN\">Evogene Ltd.</a> has announced the completion of its transaction with ICL Group Ltd., involving the divestiture of the majority of Lavie Bio Ltd.'s activities and assets. This transaction includes the transfer of Lavie Bio's proprietary Biology Driven Design technology platform, microbial bank, and pipeline of advanced development programs to ICL. Evogene has also transferred its MicroBoost AI for AG platform to ICL. The strategic move aligns with Evogene's strategy to enhance the value of its subsidiaries and technology, while ICL aims to strengthen its position in the ag-biologicals market by integrating Lavie Bio's capabilities with its own expertise and global reach. Existing strategic partnerships and commercial agreements of Lavie Bio remain unaffected and under its ownership.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Evogene Ltd. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001178913-25-002325), on July 08, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"CTVA","symbol_name":"Corteva, Inc.","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250708:nNDL5z2dYC:1","article_id":"2549493205","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2549493205","pubTimestamp":1751972452,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"Evogene Ltd. has announced the completion of its transaction with ICL Group Ltd., involving the divestiture of the majority of Lavie Bio Ltd.'s activities and assets. This transaction includes the transfer of Lavie Bio's proprietary Biology Driven Design technology platform, microbial bank, and pipeline of advanced development programs to ICL. Evogene has also transferred its MicroBoost AI for AG platform to ICL. The strategic move aligns with Evogene's strategy to enhance the value of its subsidiaries and technology, while ICL aims to strengthen its position in the ag-biologicals market by integrating Lavie Bio's capabilities with its own expertise and global reach. Existing strategic partnerships and commercial agreements of Lavie Bio remain unaffected and under its ownership.","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"CTVA":"Corteva, Inc.","BK4588":"碎股","LU0612318971.USD":"BGF NATURAL RESOURCES \"A5G\" (USD) INC","LU0630314457.HKD":"NINETY ONE GSF GLOBAL NATURAL RESOURCES \"A\" (HKD) ACC","BK4585":"ETF&股票定投概念","LU0612318385.USD":"BGF NATURAL RESOURCES \"A2\" (USD) ACC","LU0300736062.USD":"FRANKLIN NATURAL RESOURCES \"A\" (USD) ACC","BK4535":"淡马锡持仓","LU0345780950.USD":"NINETY ONE GSF GLOBAL NATURAL RESOURCES \"A\" (USD) ACC","LU1430597077.USD":"BGF NATURAL RESOURCES \"A\" (USD) INC","LU1506573853.SGD":"MANULIFE GF GLOBAL EQUITY \"AA\" (SGD) INC","LU0654597011.USD":"BGF NATURAL RESOURCES \"A4G\" (USD) INC","LU0300736492.USD":"FRANKLIN NATURAL RESOURCES \"A\" (USD) INC","LU0345781412.USD":"NINETY ONE GSF GLOBAL NATURAL RESOURCES \"A\" (USD) INC","BK4139":"生物科技","EVGN":"Evogene Ltd.","BK4093":"化肥与农用药剂","SG9999002521.SGD":"United Global Resources A Acc SGD"},"translate_title":"Evogene完成将Lavie Bio业务出售给ICL，转让关键技术平台","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"CTVA":0.9,"EVGN":0.9},"content_text":"Evogene Completes Sale of Lavie Bio's Activities to ICL, Transferring Key Technology Platforms\n    \n\nEvogene Ltd. has announced the completion of its transaction with ICL Group Ltd., involving the divestiture of the majority of Lavie Bio Ltd.'s activities and assets. This transaction includes the transfer of Lavie Bio's proprietary Biology Driven Design technology platform, microbial bank, and pipeline of advanced development programs to ICL. Evogene has also transferred its MicroBoost AI for AG platform to ICL. The strategic move aligns with Evogene's strategy to enhance the value of its subsidiaries and technology, while ICL aims to strengthen its position in the ag-biologicals market by integrating Lavie Bio's capabilities with its own expertise and global reach. Existing strategic partnerships and commercial agreements of Lavie Bio remain unaffected and under its ownership.\n      \n\nDisclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Evogene Ltd. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001178913-25-002325), on July 08, 2025, and is solely responsible for the information contained therein.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"event","news_rank":0,"symbols":[],"gpt_button":0,"code":"91000000","status":"200"}}}